Shots:
- Abbott has received European CE Mark for its Volt PFA System to treat pts with atrial fibrillation; commercialization has begun, with further expansion in EU markets expected by H2’25
- Approval was based on CE Mark study in the EU & Australia, showing that the Volt achieved pulmonary vein isolation (PVI) in 99.1% veins with fewer energy applications than other marketed PFA systems
- Volt, integrated with Abbott’s EnSite X EP system, provides simplified workflow, efficient energy delivery via its balloon-in-basket design, plus procedural flexibility with sedation options & is being evaluated in the VOLT-AF IDE study, which completed early enrollment (n~400), with 12mos. follow-up expected in 2025
Ref: Prnewswire | Image: Abbott
Related News:- Abbott Reports First-in-Human Leadless Pacing Procedures Using AVEIR Conduction System Pacing (CSP) Leadless Pacemaker
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
